At a glance
- Vapreotide is not an FDA-approved drug: Drugs@FDA has no record of it.
- PubMed lists 237 publications mentioning it, including 4 randomized controlled trials and 79 animal-only studies.
- ClinicalTrials.gov lists 2 registered studies testing it (0 active).
- FDA's adverse event system (FAERS) holds 1 report mentioning it; 0 classified as serious. Reports do not prove causation.
Research topics
Most frequent MeSH subject headings in the latest PubMed records (English, as indexed).
Regulatory status
Drugs@FDA applications
No application found in Drugs@FDA, FDA's database of approved drugs.
Source: Drugs@FDA (openFDA) · verified October 30, 2026 · API query
FDA compounding safety list
Not on FDA's list of bulk drug substances that may present significant safety risks in compounding.
Source: FDA.gov — Category 2 bulk drug substances · verified October 30, 2026
Removal of a substance from a regulatory list does not mean it has been approved. A "research use only" label does not make a product safe or legal for human use.
Scientific publications
Counts are PubMed records that mention the peptide in the title or abstract. Categories overlap, and a mention is not the same as testing the peptide as a treatment. Each number opens the exact PubMed search. Effects seen in laboratory or animal studies may not occur in humans. A registered clinical trial does not show that a substance is effective or safe.
Latest publications
- The influence of somatostatin analogues on the incidence of pancreatic fistulas and postoperative morbidity in patients undergoing pancreatic resection: A Bayesian network meta-analysis.
- Investigation into in silico and in vitro approaches for inhibitors targeting MCM10 in Leishmania donovani: a comprehensive study.
- Targeting of essential mycobacterial replication enzyme DnaG primase revealed Mitoxantrone and Vapreotide as novel mycobacterial growth inhibitors.
- Octreotide and postoperative pancreatic fistula after pancreaticoduodenectomy: What we know so far? A narrative review.
- Does care fragmentation in patients with bladder cancer lead to worse outcomes?
- Neuroprotective Effects of Vapreotide on Tau Transfection-Induced Neurodegeneration.
- Do somatostatin-analogues have the same impact on postoperative morbidity and pancreatic fistula in patients after pancreaticoduodenectomy and distal pancreatectomy? - A systematic review with meta-analysis of randomized-controlled trials.
- State-of-the-art tools unveil potent drug targets amongst clinically approved drugs to inhibit helicase in SARS-CoV-2.
- A plausible way for excretion of metal nanoparticles via active targeting.
- Green dual-template synthesis of AgPd core-shell nanoparticles with enhanced electrocatalytic activity.
Source: PubMed (NCBI) · verified October 30, 2026
Clinical trials
- Registered
- 2
- Active
- 0
- With posted results
- 0
Conditions studied
| Study | Status | Phase | Start |
|---|---|---|---|
| Use of Sanvar® With Endoscopic Treatment for the Control of Acute Variceal Bleeding | Completed | Phase 3 | May 2006 |
| Vapreotide in Treating Patients Undergoing Elective Pancreatic Resection | Terminated | Phase 3 | Mar 2001 |
All 2 studies on ClinicalTrials.gov ↗
Source: ClinicalTrials.gov · verified October 30, 2026
Adverse event reports
- Reports
- 1
- Serious
- 0
- With death outcome
- 0
Most reported reactions
Adverse event reports do not prove that the substance caused these effects. Side effects not listed here may still occur. Reaction terms are MedDRA terms as reported to FAERS.
Source: FDA FAERS (FAERS data as of July 30, 2026) · verified October 30, 2026 · API query
Change history
No changes since monitoring began on October 30, 2026.